Core Scientific shares declined as investors assessed regulatory scrutiny surrounding its Texas expansion and substantial capital expenditure requirements.
Core Scientific (CORZ) is down 3.0% today. While a single fresh negative catalyst is not immediately apparent, the pullback appears tied to investor caution surrounding the company’s aggressive expansion strategy. The market seems to be weighing Core Scientific’s substantial recent growth initiatives against regulatory uncertainty in Texas, the significant cash outlay required for its latest acquisition, and persistent accounting losses linked to warrants.
On August 14, Core Scientific completed its acquisition of Polaris DS, securing approximately 440 megawatts of grid-connected power capacity for roughly $444 million in cash and advancing its Muskogee campus expansion plan. However, Texas has temporarily paused approvals for new data center projects while the Electric Reliability Council of Texas (ERCOT) and the Public Utility Commission of Texas (PUCT) conduct an audit process. This regulatory pause introduces uncertainty for operators with expansion exposure in the state. Although Core Scientific stated on August 10 that it supports the Texas review process, the broader policy shift continues to raise questions regarding the timing of data center development and grid interconnection.
In its second-quarter 2026 earnings report, Core Scientific highlighted strong revenue growth and increased leased capacity. However, the company also reported a net loss, which was primarily driven by adjustments to the fair value of warrants. These accounting dynamics continue to fuel investor concerns regarding potential dilution and valuation.
Regarding market activity, Core Scientific insiders have executed 39 trades in the open market over the past six months, comprising one purchase and 38 sales. Concurrently, institutional positioning shows 223 investors adding shares to their portfolios, while 225 have reduced their positions in the most recent quarter.
On the research front, Wall Street coverage remains cautiously optimistic. Over the past several months, one firm has issued a buy rating for the stock, with zero firms issuing sell ratings. Additionally, ten analysts have published price targets within the last six months, establishing a median target of $31.00.
*Disclaimer: This price movement analysis was generated with the assistance of artificial intelligence. Readers are advised to verify all information independently. This article does not constitute financial advice. Please refer to Quiver Quantitative’s full disclaimers for additional details. Note that minor inaccuracies may occur due to ticker-mapping errors or other data anomalies.*